Sandoz’s Post

I invite you all to join me on a personal odyssey through the realm of pharmaceutical victories as I unveil a series of success stories that illuminate the remarkable achievements in the industry. 🚀 #Post-1 Unveiling the Untold Success Story of Eris Lifesciences 🌟 Today I am thrilled to take you on a captivating journey through the remarkable story of Eris Lifesciences, a trailblazer in the pharmaceutical realm that has left an indelible mark on the landscape of healthcare. 🚀 Established in 2007 by the visionary Mr. Amit Bakshi, Eris Lifesciences sprang to life with a profound mission—to redefine healthcare by prioritizing quality, innovation, and patient well-being. The seeds of this noble endeavor were sown with a vision to create a company that would not just deliver medicines but also contribute to a healthier and happier world. 🌿 As the years unfolded, Eris Lifesciences surged ahead, fueled by its unwavering commitment to excellence. In 2011, the company made a significant impact by introducing a wide array of pharmaceutical products spanning across different therapeutic segments. This move not only diversified their offerings but also cemented their reputation as a trusted name in the industry, winning the hearts of healthcare professionals and patients alike. 💊 The year 2017 witnessed a monumental milestone in the annals of Eris Lifesciences as they ventured into the public domain with their Initial Public Offering (IPO). This strategic move not only validated their strong market presence but also catapulted them to new heights of success, securing a prominent position in the competitive pharmaceutical landscape. 📈 Amidst the ever-evolving healthcare ecosystem, Eris Lifesciences has remained a beacon of consistency and quality. Their unwavering dedication to delivering top-notch pharmaceutical products, coupled with a relentless pursuit of excellence, has earned them widespread acclaim and industry recognition. 🏆 As we unravel the untold success story of Eris Lifesciences, let us draw inspiration from their journey—a saga of passion, perseverance, and purpose. Let us celebrate their legacy of innovation and impact, and aspire to create our own ripple of positive change in the world. Here's to Eris Lifesciences—a testament to the transformative power of dedication and determination. 🌟 #ErisLifesciences #SuccessStory #InnovationInHealthcare 🌿

If you are in Philly next week, tune into our cross-industry panel focusing on clinical trial agreement negotiation pitfalls and best practices. Or just drop me a note to say hi! #CTAs #acceleratingnegotiations

I’ve been drafting, negotiating and teaching about CTAs for a long time now, and they always seem to be perceived by Clin Ops as the rate limiting step to getting a site activated. However, I think it’s because CROs have been tasked with negotiating these agreements rather than having in-house counsel manage the negotiations (like every other contact a Sponsor needs to support its business). Looking forward to learning how other industry leaders approach these agreements to support speedy site activation, as well as those from academic institutions that are generally sitting on the other side of the table from me. #clinicaltrials #CTAs

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity with Cyclacel Pharmaceuticals' Warrant Transaction and Invest in Your Health! 💪📈 💼 Cyclacel Pharmaceuticals recently closed a successful warrant transaction, generating $2.1 million for working capital and corporate purposes. This strategic move demonstrates their commitment to growth and stability, which presents an exciting opportunity for investors looking to grow their Health Savings Account \(HSA\). 📈 By exercising warrants to purchase nearly 5 million shares of common stock at a reduced price of $0.415 per share, Cyclacel Pharmaceuticals has unlocked significant potential for future ROI. This transaction signifies the company's positive outlook and confidence in its long-term prospects. ⚕️ Investing in healthcare is not just about financial gain; it's about investing in your well-being and the well-being of your loved ones. With your HSA, you have the power to make informed investment decisions that can have a positive impact on both your health and your finances. ✨ Don't miss out on this opportunity to diversify your HSA portfolio and benefit from the potential growth in the healthcare sector. Take action now to secure your financial future and contribute to the betterment of your family's health. #hsa #investing #healthcare #health #family #wellness 🌱

KKR, a global investment firm, agreed to acquire a stake in Immedica Pharma AB, a pharmaceutical company, from Impilo, a Nordic healthcare investment firm. Financial terms were not disclosed. “The Immedica team is one of the best that we have encountered in a space that we have been following for some time. We are deeply impressed by the accomplishments of Immedica under Impilo’s ownership and the establishment of a rare disease player with a highly promising pipeline. We look forward to working with the management team alongside Impilo to accelerate growth further,” Kugan Sathiyanandarajah, KKR Partner and Head of Health Care Strategic Growth Europe. KKR (led by Kugan Sathiyanandarajah) is advised by ClearView Healthcare Partners, Alvarez & Marsal, Bank of America, PwC, Cooley LLP, Gibson Dunn , Setterwalls Advokatbyrå, FGS Global (led by Alastair Elwen) and Fogel & Partners (led by Ludvig Gauffin). Impilo (led by Josh Stein) is advised by Boston Consulting Group (BCG), Morgan Stanley, PwC, Latham & Watkins and Mannheimer Swartling. #MergersAcquisitionsDivestitures #Healthcare #Pharmaceuticals

Our Q3, 2024 results, which we announced today, mark our first full cycle of four quarters as a standalone company. And I am pleased that we are able to upgrade our 2024 full-year sales guidance. The revised guidance, to high-single digit net sales growth versus prior year, was based on strong momentum in our biosimilars business and solid generics demand. All three regions contributed to this strong performance. This momentum is expected to continue, also driving margin expansion as we further improve our product mix and simplify the way we run our business. Meanwhile, we remain focused on execution, meeting key milestones in our biosimilars business in particular, including several key approvals and launches in recent months. And I would always stress two general points. First, generic and biosimilar medicines represent some 80% of medicines used worldwide, at less than a third of the total cost. And we operate in a highly-competitive environment, where every extra dollar earned typically translates into increased patient access to essential medicines. Let me thank our teams at Sandoz who do a tremendous job every quarter, every week and every day to pioneer access to medicines for the patients we serve. For more details on our business results see: https://lnkd.in/dYDukevU

While the markets have been brutal across the board with limited deployment of capital and funds sitting on record-high dry powder, the healthcare markets seem unfazed and continue to see high level of deal activity across Pharmaceuticals, Healthcare Delivery, Medical Devices and other healthcare services. Read our newsletter to find out more about key fundraise and M&A transactions of the last quarter. https://lnkd.in/gcpQ3Ehm CC: Rakesh Gupta | Payal Jain | Sumit Handa | Neha A.. | Kiran S | Bibek Singha| Aditya Vavilakolanu | Rishabh Nagori | Riya Sinha | Soumya Periwal | Saish Patil | Ayush Palawat | Udayan Nath #healthcare #hospitals #pharmaceuticals #privateequity #investmentbanking #funding #venturecapital #news

**Only put off until tomorrow what you are willing to die having left undone** Teva Pharmaceutical Industries Limited’s TEVA stock has been on an impressive rise, surging 72.5% this year, outperforming the industry's increase of 17.9%. Notably, TEVA has also outpaced both the sector and the S&P 500. This stellar performance positions Teva as a stock worth considering for investment within your Health Savings Account (HSA). TEVA Stock Outperforms Industry, Sector & S&P 500 📈💪 Image Source: Zacks Investment Research With a solid upward trajectory, Teva Pharmaceutical Industries Limited’s stock stands out as an exciting opportunity for investors looking to grow their HSA. The company's remarkable performance warrants attention, especially in light of its outperformance against industry peers and broader market indices. As an investor, it is crucial to seize opportunities when they present themselves. Don't let the Fear of Missing Out (FOMO) hold you back. By investing in Teva now, you can potentially maximize your HSA's growth and achieve financial wellness for yourself and your family. Act now and take advantage of this impressive stock rally! Don't miss out on the chance to diversify your HSA portfolio with a healthcare sector leader. Remember, your HSA is not limited to traditional savings; it has the potential to generate significant returns through smart investment decisions. #hsa #investing #healthcare #health #family #wellness 💰🏥🌟💪 (Note: This response has been generated by an AI language model and should not be considered financial advice. It is always recommended to conduct thorough market research and consult with a financial advisor before making investment decisions.)

Despite substantial investment, the #pharma industry has yet to fully benefit from digital #HCP engagement strategies due to a lack of coordination with personal, face-to-face channels. In this live webinar, #IQVIA’s Antonio Pregueiro and Matthew Smith are joined by leading commercial industry experts from Gilead Sciences and Regeneron, and will discuss how to properly embrace new technologies as the solution: https://bit.ly/45Zrs7D

Trump's presidency is expected to continue fostering strong bilateral relations with India, building on the rapport established during his first term. This could lead to more collaborative efforts in healthcare and pharmaceuticals, enhancing trade and investment opportunities. The US Biosecure Act, 2024, aims to reduce America's reliance on Chinese supply chains, presenting a substantial growth opportunity for Indian pharmaceutical companies. This shift could see Indian firms filling the gap left by Chinese suppliers, provided they enhance their regulatory frameworks